2-Ethoxy-1-ethylnaphthalene | 17295-04-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 2-Ethoxy-1-ethylnaphthalene
• CAS: 17295-04-4
• 化学式: C₁₄H₁₆O
• 分子量: 200.28
• InChiKey: FKQIZEDHPDFQRR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-萘酚 、 正丁基锂 、 硫酸二乙酯 以5%的产率得到
  参考文献：
  名称：

  SAIDI, M. R., INDIAN J. CHEM., 1982, 21, N 5, 474

  摘要：

  DOI：

文献信息

• ORGANIC COMPOUNDS AND THEIR USES
  申请人：Brandl Trixl

  公开号：US20100204159A1

  公开（公告）日：2010-08-12

  The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.

  本申请描述了对人类疾病的治疗、预防和/或改善有用的有机化合物。
• Piperidine derivatives having ccr3 antagonism
  申请人：Matsumoto Yoshiyuki

  公开号：US20070032525A1

  公开（公告）日：2007-02-08

  The invention provides low molecular compounds having activity which inhibits binding of CCR3 ligands to CCR3 on target cells, i.e. CCR3 antagonists. The invention also provides compounds represented by formula (I) below, pharmaceutically acceptable acid adducts thereof, or pharmaceutically acceptable C 1 -C 6 alkyl adducts thereof, as well as pharmaceutical compositions comprising them as effective ingredients, which are useful for treatment or prevention of diseases associated with CCR3, such as asthma and allergic rhinitis.

  本发明提供了具有抑制CCR3配体结合到靶细胞CCR3的活性的低分子化合物，即CCR3拮抗剂。本发明还提供了由下式（I）表示的化合物，其药学上可接受的酸加合物或药学上可接受的C1-C6烷基加合物，以及包含它们作为有效成分的制药组合物，用于治疗或预防与CCR3相关的疾病，例如哮喘和过敏性鼻炎。
• 4,4-Disubstituted) piperidine derivatives having ccr3 antagonism
  申请人：Matsumoto Yoshiyuki

  公开号：US20070037851A1

  公开（公告）日：2007-02-15

  The invention provides low molecular compounds having activity which inhibits binding of CCR3 ligands to CCR3 on target cells, i.e. CCR3 antagonists. The invention also provides 4,4-(disubstituted)piperidine derivatives represented by formula (I) below, pharmaceutically acceptable acid adducts thereof, or pharmaceutically acceptable C 1 -C 6 alkyl adducts thereof, as well as pharmaceutical compositions comprising them as effective ingredients, which are useful for treatment or prevention of diseases associated with CCR3, such as asthma and allergic rhinitis.

  本发明提供了具有抑制CCR3配体与靶细胞上CCR3结合活性的低分子化合物，即CCR3拮抗剂。本发明还提供了由下式（I）所表示的4,4-(二取代)哌啶衍生物，其药学上可接受的酸加合物或药学上可接受的C1-C6烷基加合物，以及包含它们作为有效成分的药物组合物，用于治疗或预防与CCR3相关的疾病，如哮喘和过敏性鼻炎。
• NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS
  申请人：PFIZER INC.

  公开号：US20160229847A1

  公开（公告）日：2016-08-11

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula II as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  本发明揭示了化合物及其药学上可接受的盐，其中该化合物具有规定在规范中的II式结构。还揭示了相应的药物组合物、治疗方法、合成方法和中间体。
• FILM, LAMINATE, SEMICONDUCTOR WAFER WITH FILM LAYER, SEMICONDUCTOR MOUNTING SUBSTRATE WITH FILM LAYER, AND SEMICONDUCTOR DEVICE
  申请人：MITSUBISHI GAS CHEMICAL COMPANY, INC.

  公开号：EP3992231A1

  公开（公告）日：2022-05-04

  A film containing: a propenyl group-containing resin (A) including, at an end of a molecule, a constituent unit represented by the following formula (1); a radical polymerizable resin or compound (B) other than the propenyl group-containing resin (A); and a curing accelerator (C), wherein the radical polymerizable resin or compound (B) includes at least one selected from the group consisting of a maleimide group and a citraconimide group. In the formula (1), -* represents a bonding hand.

  一种薄膜，包含：含丙烯基团的树脂（A），其分子末端包括由下式（1）表示的组成单元；除含丙烯基团的树脂（A）之外的可自由基聚合的树脂或化合物（B）；以及固化促进剂（C），其中可自由基聚合的树脂或化合物（B）包括至少一种从马来酰亚胺基团和柠康酰亚胺基团组成的组中选出的基团。在式 (1) 中，-* 代表键手。